Canadian Blood Services is pushing to strengthen Canada’s self‑reliance in plasma‑derived medicines. Demand for immunoglobulins continues to rise, yet most of Canada’s supply still comes from the United States. CBS outlines a national strategy to expand plasma collection, build Canadian manufacturing capacity, and reduce reliance on foreign supply chains. The goal is long‑term stability and improved self‑sufficiency for patients who depend on these lifesaving therapies.
Read the full story here: https://www.blood.ca/en/about-us/media/newsroom/why-made-canada-must-apply-lifesaving-medicines
